Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AIDX

20/20 Biolabs Inc

Apr 17 • 04:00PM ET

1.78

+0.06 3.49 %

Healthcare • Medical Devices • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	64.32%	Shs Outstand	10.44M	Perf Week	-5.32%
Market Cap	18.65M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.74M	Perf Month	-10.10%
Enterprise Value	19.03M	PEG	-	EPS next Q	-	Inst Own	0.00%	Short Float	1.45%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	22.75%	Short Ratio	0.17	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.05M	Perf YTD	-92.54%
Book/sh	-0.01	P/C	18.11	EPS next 5Y	-	ROE	-	52W High	50.00 -96.44%	Perf Year	-
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	- 3.60%	ROIC	-	52W Low	1.51 17.88%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-43.03% -2.58%	Gross Margin	-	Volatility	7.41% 11.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	4.55%	Oper. Margin	-	ATR (14)	0.78	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.55	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	9.94	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.60	EPS Q/Q	65.22%	SMA20	-2.58%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	60.23%	SMA50	-49.50%	Rel Volume	0.30	Prev Close	1.72
Employees	14	LT Debt/Eq	-	Earnings	-	SMA200	-49.50%	Avg Volume	320.65K	Price	1.78
IPO	Feb 19, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	96,432	Change	3.49%

Apr-13-26 07:00AM	HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference (TMX Newsfile)
Apr-07-26 08:31AM	20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest for Cancer Through Evexia Platform (GlobeNewswire) -5.45%
Mar-31-26 04:57PM	20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress (GlobeNewswire) +5.62%
Mar-27-26 08:31AM	Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest Multi-Cancer Early Detection Blood Test (GlobeNewswire)
Mar-24-26 08:31AM	20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program (GlobeNewswire) -17.59%
07:00AM	Loading…
Mar-19-26 07:00AM	HEALWELL AI Delivers Record Revenue and First Year of Positive Adjusted EBITDA as Global AI Platform Strategy Takes Hold (TMX Newsfile) -5.05%
Mar-12-26 08:31AM	20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies (GlobeNewswire) -8.49%
Feb-25-26 08:31AM	20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities (GlobeNewswire) -28.82%
Feb-20-26 08:31AM	20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time (GlobeNewswire) -38.04%
Feb-19-26 09:00AM	20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth (GlobeNewswire)

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIDX

20/20 Biolabs Inc

Upgrade your Finviz experience